Selected research
Industry Research
CGRP Targeting Drugs Industry Research Report 2026
Market perspective
The global CGRP Targeting Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the CGRP Targeting Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the CGRP Targeting Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the CGRP Targeting Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of CGRP Targeting Drugs include Alder Therapeutics, AbbVie Inc., Amgen Inc., Daiichi Sankyo Co., Ltd., Pfizer Inc., Lilly Inc., Lundbeck, Novartis International AG and Teva. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global CGRP Targeting Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to CGRP Targeting Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CGRP Targeting Drugs Market by Company
Alder Therapeutics
AbbVie Inc.
Amgen Inc.
Daiichi Sankyo Co., Ltd.
Pfizer Inc.
Lilly Inc.
Lundbeck
Novartis International AG
Teva
CGRP Targeting Drugs Segment by Type
CGRP Receptor Antagonists
CGRP Monoclonal Antibodies
CGRP Targeting Drugs Segment by Application
Specialty Clinic
Hospital
Others
CGRP Targeting Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CGRP Targeting Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CGRP Targeting Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CGRP Targeting Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of CGRP Targeting Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CGRP Receptor Antagonists
- CGRP Monoclonal Antibodies
Applications
- Specialty Clinic
- Hospital
- Others
Companies covered
- Alder Therapeutics
- AbbVie Inc.
- Amgen Inc.
- Daiichi Sankyo Co., Ltd.
- Pfizer Inc.
- Lilly Inc.
- Lundbeck
- Novartis International AG
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 CGRP Targeting Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 CGRP Receptor Antagonists
- 2.2.3 CGRP Monoclonal Antibodies
- 2.3 CGRP Targeting Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Specialty Clinic
- 2.3.3 Hospital
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 CGRP Targeting Drugs Breakdown Data by Type
- 3.1 Global CGRP Targeting Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global CGRP Targeting Drugs Forecasted Market Size by Type (2027-2032)
4 CGRP Targeting Drugs Breakdown Data by Application
- 4.1 Global CGRP Targeting Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global CGRP Targeting Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global CGRP Targeting Drugs Market Perspective (2021-2032)
- 5.2 Global CGRP Targeting Drugs Growth Trends by Region
- 5.2.1 Global CGRP Targeting Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 CGRP Targeting Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 CGRP Targeting Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 CGRP Targeting Drugs Market Dynamics
- 5.3.1 CGRP Targeting Drugs Industry Trends
- 5.3.2 CGRP Targeting Drugs Market Drivers
- 5.3.3 CGRP Targeting Drugs Market Challenges
- 5.3.4 CGRP Targeting Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top CGRP Targeting Drugs Players by Revenue
- 6.1.1 Global Top CGRP Targeting Drugs Players by Revenue (2021-2026)
- 6.1.2 Global CGRP Targeting Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global CGRP Targeting Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of CGRP Targeting Drugs Head Office and Area Served
- 6.4 Global CGRP Targeting Drugs Players, Product Type & Application
- 6.5 Global CGRP Targeting Drugs Manufacturers Established Date
- 6.6 Global CGRP Targeting Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America CGRP Targeting Drugs Market Size (2021-2032)
- 7.2 North America CGRP Targeting Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America CGRP Targeting Drugs Market Size by Country (2021-2026)
- 7.4 North America CGRP Targeting Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe CGRP Targeting Drugs Market Size (2021-2032)
- 8.2 Europe CGRP Targeting Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe CGRP Targeting Drugs Market Size by Country (2021-2026)
- 8.4 Europe CGRP Targeting Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific CGRP Targeting Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific CGRP Targeting Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific CGRP Targeting Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific CGRP Targeting Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America CGRP Targeting Drugs Market Size (2021-2032)
- 10.2 South America CGRP Targeting Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America CGRP Targeting Drugs Market Size by Country (2021-2026)
- 10.4 South America CGRP Targeting Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa CGRP Targeting Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa CGRP Targeting Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa CGRP Targeting Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa CGRP Targeting Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Alder Therapeutics
- 12.1.1 Alder Therapeutics Company Information
- 12.1.2 Alder Therapeutics Business Overview
- 12.1.3 Alder Therapeutics Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.1.4 Alder Therapeutics CGRP Targeting Drugs Product Portfolio
- 12.1.5 Alder Therapeutics Recent Developments
- 12.2 AbbVie Inc.
- 12.2.1 AbbVie Inc. Company Information
- 12.2.2 AbbVie Inc. Business Overview
- 12.2.3 AbbVie Inc. Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.2.4 AbbVie Inc. CGRP Targeting Drugs Product Portfolio
- 12.2.5 AbbVie Inc. Recent Developments
- 12.3 Amgen Inc.
- 12.3.1 Amgen Inc. Company Information
- 12.3.2 Amgen Inc. Business Overview
- 12.3.3 Amgen Inc. Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.3.4 Amgen Inc. CGRP Targeting Drugs Product Portfolio
- 12.3.5 Amgen Inc. Recent Developments
- 12.4 Daiichi Sankyo Co., Ltd.
- 12.4.1 Daiichi Sankyo Co., Ltd. Company Information
- 12.4.2 Daiichi Sankyo Co., Ltd. Business Overview
- 12.4.3 Daiichi Sankyo Co., Ltd. Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.4.4 Daiichi Sankyo Co., Ltd. CGRP Targeting Drugs Product Portfolio
- 12.4.5 Daiichi Sankyo Co., Ltd. Recent Developments
- 12.5 Pfizer Inc.
- 12.5.1 Pfizer Inc. Company Information
- 12.5.2 Pfizer Inc. Business Overview
- 12.5.3 Pfizer Inc. Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.5.4 Pfizer Inc. CGRP Targeting Drugs Product Portfolio
- 12.5.5 Pfizer Inc. Recent Developments
- 12.6 Lilly Inc.
- 12.6.1 Lilly Inc. Company Information
- 12.6.2 Lilly Inc. Business Overview
- 12.6.3 Lilly Inc. Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.6.4 Lilly Inc. CGRP Targeting Drugs Product Portfolio
- 12.6.5 Lilly Inc. Recent Developments
- 12.7 Lundbeck
- 12.7.1 Lundbeck Company Information
- 12.7.2 Lundbeck Business Overview
- 12.7.3 Lundbeck Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.7.4 Lundbeck CGRP Targeting Drugs Product Portfolio
- 12.7.5 Lundbeck Recent Developments
- 12.8 Novartis International AG
- 12.8.1 Novartis International AG Company Information
- 12.8.2 Novartis International AG Business Overview
- 12.8.3 Novartis International AG Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.8.4 Novartis International AG CGRP Targeting Drugs Product Portfolio
- 12.8.5 Novartis International AG Recent Developments
- 12.9 Teva
- 12.9.1 Teva Company Information
- 12.9.2 Teva Business Overview
- 12.9.3 Teva Revenue in CGRP Targeting Drugs Business (2021-2026)
- 12.9.4 Teva CGRP Targeting Drugs Product Portfolio
- 12.9.5 Teva Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst